Patients with tumours showing high HSP70 expression may benefit more from HSP70-targeted therapies, guiding clinicians in selecting the most effective interventions to mitigate metastasis, drug resistance and relapse [58]. The gene discussed is HSPA1A; the disease is neoplasm.